41.87
1.74%
-0.74
Ultragenyx Pharmaceutical Inc. (RARE) 最新ニュース
Ultragenyx given Ritter Center Corporate Impact Award - North Bay Business Journal
North Bay Business Journal
Ultragenyx given Ritter Center Corporate Impact Award - North Bay Business Journal
North Bay Business Journal
Nanoscope Therapeutics Appoints SVP of Regulatory and Quality - dallasinnovates.com
dallasinnovates.com
Nanoscope Therapeutics Appoints SVP of Regulatory and Quality - dallasinnovates.com
dallasinnovates.com
MSN - MSN
MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Amalgamated Bank Purchases 1427 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
M&T Bank Corp Takes $310000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
Ultragenyx maintains Outperform rating amid ION582 data release By Investing.com - Investing.com Canada
Investing.com Canada
Ultragenyx maintains Outperform rating amid ION582 data release - Investing.com Australia
Investing.com Australia
Ultragenyx maintains Outperform rating amid ION582 data release - Investing.com
Investing.com
Swiss National Bank Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
Mucopolysaccharidosis Type I Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, by ... - openPR
openPR
Van ECK Associates Corp Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
Learn to Evaluate (RARE) using the Charts - Stock Traders Daily
Stock Traders Daily
Ultragenyx: 1Q Earnings Snapshot - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Ultragenyx reports serious adverse effects in gene therapy trial - MSN
MSN
Ultragenyx Pharmaceutical (RARE) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
At Ultragenyx Emil Kakkis is getting creative in the fight against ultrarare disease - San Francisco Business Times - The Business Journals
The Business Journals
RARE December 2025 Options Begin Trading - Nasdaq
Nasdaq
At Ultragenyx Emil Kakkis is getting creative in the fight against ultrarare disease - The Business Journals
The Business Journals
Ultragenyx to Participate at Bank of America's 2024 - GlobeNewswire
GlobeNewswire
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference - Yahoo Finance
Yahoo Finance
Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Defense World
Russell Investments Group Ltd. Acquires 16728 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $109.00 by Analysts at Canaccord Genuity Group - MarketBeat
MarketBeat
Ultragenyx: 2Q Earnings Snapshot - Yahoo Canada Shine On
Yahoo Canada Shine On
Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com Australia
Investing.com Australia
Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com Australia
Investing.com Australia
Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com UK
Investing.com UK
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Zacks Investment Research
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $47.00 - MarketBeat
MarketBeat
Earnings call: Ultragenyx Q1 2024 results show strong clinical progress - Investing.com
Investing.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $47.00 - MarketBeat
MarketBeat
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Yahoo Finance
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research
Zacks Investment Research
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
GlobeNewswire
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire Inc.
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
GlobeNewswire
Repligen (RGEN) Misses Q1 Earnings Estimates
Zacks Investment Research
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Buys 548 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Defense World
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143 ... - Yahoo Finance
Yahoo Finance
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire Inc.
Ultragenyx Earns Award for Outstanding Contributions to the Massachusetts Economy - The Bedford Citizen
The Bedford Citizen
大文字化:
|
ボリューム (24 時間):